GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » uniQure NV (FRA:UQ1) » Definitions » EBITDA Margin %

uniQure NV (FRA:UQ1) EBITDA Margin % : -751.55% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is uniQure NV EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. uniQure NV's EBITDA for the three months ended in Dec. 2023 was €-46.10 Mil. uniQure NV's Revenue for the three months ended in Dec. 2023 was €6.13 Mil. Therefore, uniQure NV's EBITDA margin for the quarter that ended in Dec. 2023 was -751.55%.


uniQure NV EBITDA Margin % Historical Data

The historical data trend for uniQure NV's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

uniQure NV EBITDA Margin % Chart

uniQure NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,561.88 -338.45 66.33 -101.44 -1,597.56

uniQure NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.03 -1,358.46 -2,430.64 -5,090.14 -751.55

Competitive Comparison of uniQure NV's EBITDA Margin %

For the Biotechnology subindustry, uniQure NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


uniQure NV's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, uniQure NV's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where uniQure NV's EBITDA Margin % falls into.



uniQure NV EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

uniQure NV's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-232.093/14.528
=-1,597.56 %

uniQure NV's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-46.1/6.134
=-751.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


uniQure NV  (FRA:UQ1) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


uniQure NV EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of uniQure NV's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


uniQure NV (FRA:UQ1) Business Description

Traded in Other Exchanges
Address
Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

uniQure NV (FRA:UQ1) Headlines

No Headlines